Effect of glabridin on collagen deposition in liver and amelioration of hepatocyte destruction in diabetes rats

Komolkriengkrai,Manaras; Nopparat,Jongdee; Vongvatcharanon,Uraporn; Anupunpisit,Vipavee; Khimmaktong,Wipapan

doi:10.3892/etm.2019.7664

Effect of glabridin on collagen deposition in liver and amelioration of hepatocyte destruction in diabetes rats

Authors:
- Manaras Komolkriengkrai
- Jongdee Nopparat
- Uraporn Vongvatcharanon
- Vipavee Anupunpisit
- Wipapan Khimmaktong
View Affiliations

Affiliations: Department of Anatomy, Faculty of Science, Prince of Songkla University, Hatyai, Songkhla 90110, Thailand, Department of Anatomy, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand
Published online on: June 11, 2019 https://doi.org/10.3892/etm.2019.7664
Pages: 1164-1174
Copyright: © Komolkriengkrai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abnormalities in insulin hormone levels leads to a hyperglycemic condition of diabetic mellitus. Hyperglycemia seriously induces organ and system destructions. The excessive accumulation of collagen fiber deposits occurs in inflammatory and reorganization processes of chronic liver diseases in type I insulin‑dependent diabetes. Regarding the research objective, glabridin (GLB), an active compound of licorice, was used as a daily supplement (40 mg/kg) in order to decrease hepatocyte destruction and collagen deposition in liver tissue of diabetic animals induced by streptozotocin. A total of 40 were randomly allocated to five groups (each, n=10), control, control treated with GLB (GLB), diabetic rats (DM) injected with single dose of streptozotocin (60 mg/kg) to induce a diabetic condition, diabetic rats receiving GLB (DM+GLB; 40 mg/kg) and diabetic rats treated with glibenclamide (DM+GL; 4 mg/kg). Characteristic histopathological changes in liver cells and tissues of rats were determined by Masson's trichrome staining and transmission electron microscopy (TEM). Western blotting was used to detect the expression of the key markers, collagen type I and fibronectin proteins. The histological investigation of liver tissue of the DM group revealed that the collagen fiber deposition was increased in the periportal, pericentral and perisinusoidal spaces compared with controls. Hepatocytes appeared as small and fragmented cells in TEM examination. Collagenization of the perisinusoidal space was recently demonstrated to represent a new aspect of the microvascular abnormalities and liver fibrosis. Healthy hepatocytes with round nucleus were observed following supplementation of glabridin. In addition, collagen fiber deposition was reduced in the area adjacent to the perisinusoidal space. The expression of collagen type I and fibronectin decreased strongly following glabridin supplementation in DM+GLB rats compared with DM rats, indicating that the hepatic tissue reorganization regained its normal morphology. These findings suggest that it may be beneficial to examine the role of glabridin as a therapeutic agent in diabetes treatment in future research.

View Figures

View References

1	Ban CR and Twigg SM: Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. 4:575–596. 2008. View Article : Google Scholar : PubMed/NCBI
2	Law B, Fowlkes V, Goldsmith JG, Carver W and Goldsmith EC: Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc Microanal. 18:22–34. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ikeda S, Makino H, Haramoto T, Chikata K, Kumagai I and Ota Z: Changes in glomerular extracellular matrices components in diabetic nephropathy. J Diabet Complications. 5:186–188. 1991. View Article : Google Scholar : PubMed/NCBI
4	Arthur MJ: Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 279:G245–G249. 2000. View Article : Google Scholar : PubMed/NCBI
5	Das J, Roy A and Sil PC: Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: A review. Food Funct. 3:1251–1264. 2012. View Article : Google Scholar : PubMed/NCBI
6	Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 275:2247–2250. 2000. View Article : Google Scholar : PubMed/NCBI
7	Rockey DC: The cell and molecular biology of hepatic fibrogenesis: Clinical and therapeutic implications. Clin Liver Dis. 4:319–355. 2000. View Article : Google Scholar : PubMed/NCBI
8	Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME and Gilbert RE: Transforming growth factor beta1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int. 51:1553–1567. 1994. View Article : Google Scholar
9	Benyon RC and Iredale JP: Is liver fibrosis reversible? Gut. 46:443–446. 2000. View Article : Google Scholar : PubMed/NCBI
10	Friedman SL: Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol Rev. 88:125–172. 2008. View Article : Google Scholar : PubMed/NCBI
11	Safadi R and Friedman SL: Hepatic fibrosis - role of hepatic stellate cell activation. MedGenMed. 4:272002.PubMed/NCBI
12	Walton KL, Johnson KE and Harrison CA: Targeting TGF-β mediated SMAD signaling for the prevention of fibrosis. Front Pharmacol. 8:4612017. View Article : Google Scholar : PubMed/NCBI
13	Liu T, Wang X, Karsdal MA, Leeming DJ and Genovese F: Molecular serum markers of liver fibrosis. Biomark Insights. 7:105–117. 2012. View Article : Google Scholar : PubMed/NCBI
14	Fallatah HI: Noninvasive biomarkers of liver fibrosis: An overview. Adv Hepatol. 2014:1152014.
15	Manabe R, Oh-e N and Sekiguchi K: Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem. 274:5919–5924. 1999. View Article : Google Scholar : PubMed/NCBI
16	Mabuchi A, Mullaney I, Sheard P, Hessian P, Zimmermann A, Senoo H and Wheatley AM: Role of hepatic stellate cells in the early phase of liver regeneration in rat: Formation of tight adhesion to parenchymal cells. Comp Hepatol 1 (3 Suppl). S292004. View Article : Google Scholar
17	Ala-Kokko L, Pihlajaniemi T, Myers JC, Kivirikko KI and Savolainen ER: Gene expression of type I, III, IV collagens in hepatic fibrosis induced by dimethylnitrosamine in the rat. Biochem J. 244:75–79. 1987. View Article : Google Scholar : PubMed/NCBI
18	Yokozawa T, Cho EJ, Rhyu DY, Shibahara N and Aoyagi K: Glycyrrhizae radix attenuates peroxynitrite-induced renal oxidative damage through inhibition of protein nitration. Free Radic Res. 39:203–211. 2005. View Article : Google Scholar : PubMed/NCBI
19	Mori H, Niwa K, Zheng Q, Yamada Y, Sakata K and Yoshimi N: Cell proliferation in cancer prevention; effects of preventive agents on estrogen-related endometrial carcinogenesis model and on an in vitro model in human colorectal cells. Mutat Res. 480–481, 201-207. 2001.
20	Shang H, Cao S, Wang J, Zheng H and Putheti R: Glabridin from Chinese herb licorice inhibits fatigue in mice. Afr J Tradit Complement Altern Med. 7:17–23. 2009.PubMed/NCBI
21	Yokota T, Nishio H, Kubota Y and Mizoguchi M: The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res. 11:355–361. 1998. View Article : Google Scholar : PubMed/NCBI
22	Choi EM: The licorice root derived isoflavan glabridin increases the function of osteoblastic MC3T3-E1 cells. Biochem Pharmacol. 70:363–368. 2005. View Article : Google Scholar : PubMed/NCBI
23	Gnanamoorthy M, Sridharan K, Dhayananth N and Ramesh Babu NG: Antimicrobial and anticancer potential of glycyrrhiza glabra. IJERM. 4:2349–2058. 2017.
24	Jung JC, Lee YH, Kim SH, Kim KJ, Kim KM, Oh S and Jung YS: Hepatoprotective effect of licorice, the root of Glycyrrhiza uralensis Fischer, in alcohol induced fatty liver disease. BMC Complement Altern Med. 16:192016. View Article : Google Scholar : PubMed/NCBI
25	Wu F, Jin Z and Jin J: Hypoglycemic effects of glabridin, a polyphenolic flavonoid from licorice, in an animal model of diabetes mellitus. Mol Med Rep. 7:1278–1282. 2013. View Article : Google Scholar : PubMed/NCBI
26	Hui AY, Liew CT, Go MY, Chim AM, Chan HL, Leung NV and Sung JJ: Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. Liver Int. 24:611–618. 2004. View Article : Google Scholar : PubMed/NCBI
27	Stinson RA and Hamilton BA: Human liver plasma membranes contain an enzyme activity that removes membrane anchor from alkaline phosphatase and converts it to a plasma-like form. Clin Biochem. 27:49–55. 1994. View Article : Google Scholar : PubMed/NCBI
28	Wilson PD, Franks LM, Cottell DC and Benham F: Alkaline phosphatase in mitochondria. Cell Biol Int Rep. 1:85–92. 1977. View Article : Google Scholar : PubMed/NCBI
29	Jeschke MG: The hepatic response to thermal injury: Is the liver important for postburn outcomes? Mol Med. 15:337–351. 2009. View Article : Google Scholar : PubMed/NCBI
30	Tian Z, Liu H, Su X, Fang Z, Dong Z, Yu C and Luo K: Role of elevated liver transaminase levels in the diagnosis of liver injury after blunt abdominal trauma. Exp Ther Med. 4:255–260. 2012. View Article : Google Scholar : PubMed/NCBI
31	Giannini EG, Testa R and Savarino V: Liver enzyme alteration: A guide for clinicians. CMAJ. 172:367–379. 2005. View Article : Google Scholar : PubMed/NCBI
32	Shen J, Zhang J, Wen J, Ming Q, Zhang J and Xu Y: Correlation of serum alanine aminotransferase and aspartate aminotransferase with coronary heart disease. Int J Clin Exp Med. 8:4399–4404. 2015.PubMed/NCBI
33	Schneeberger EE, Arriola MS, Fainboim H, Schroder T, González J, Baiges D, Luque M, Maldonado Coco JA and Citera G: Idiophatic inflammatory myophaties: Its association with liver disorders. Rev Fac Cien Med Univ Nac Cordoba. 69:139–143. 2012.(In Spanish). PubMed/NCBI
34	Hosseinzadeh H and Nassiri-Asl M: Pharmacological effects of glycyrrhiza spp. And its bioactive constituents: Update and review. Phytother Res. 29:1868–1886. 2015. View Article : Google Scholar : PubMed/NCBI
35	Bilal HM, Riaz F, Munir K, Saqib K and Sawa MR: Histological changes in the liver of diabetic rats: A review of pathogenesis of nonalcoholic fatty liver disease in type 1 diabetes mellitus. Cogent Medicine. 3:12754152016. View Article : Google Scholar
36	Kawano Y and Cohen DE: Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 48:434–441. 2013. View Article : Google Scholar : PubMed/NCBI
37	Nakashima O, Kurogi M, Yamaguchi R, Miyaaki H, Fujimoto M, Yano H, Kumabe T, Hayabuchi N, Hisatomi J, Sata M and Kojiro M: Unique hypervascular nodules in alcoholic liver cirrhosis: Identical to focal nodular hyperplasia-like nodules. J Hepatol. 41:992–998. 2004. View Article : Google Scholar : PubMed/NCBI
38	Pessayre D, Fromenty B and Mansouri A: Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol. 16:1095–1105. 2004. View Article : Google Scholar : PubMed/NCBI
39	Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Fernandez-Escalante JC and Pons-Romero F: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 34:1158–1163. 2001. View Article : Google Scholar : PubMed/NCBI
40	Sanyal AJ; American Gastroenterological Association, : AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 123:1705–1725. 2002. View Article : Google Scholar : PubMed/NCBI
41	Bertolani C and Marra F: The role of adipokines in liver fibrosis. Pathophysiology. 15:91–101. 2008. View Article : Google Scholar : PubMed/NCBI
42	Poisson J, Lemoinne S, Boulanger C, Durand F, Moreau R, Valla D and Rautou PE: Liver sinusoidal endothelial cells: Physiology and role in liver diseases. J Hepatol. 66:212–227. 2017. View Article : Google Scholar : PubMed/NCBI
43	Ohno T, Horio F, Tanaka S, Terada M, Namikawa T and Kitch J: Fatty liver and hyperlipidemia in IDDM (insulin dependent diabetes mellitus) of streptozotocin treated shrew. Life Sci. 66:125–131. 2000. View Article : Google Scholar : PubMed/NCBI
44	Onori P, Morini S, Franchitto A, Sferra R, Alvaro D and Gaudio E: Hepatic microvascular features in experimental cirrhosis: A structural and morphometrical study in CCI4-treated rats. J Hepatol. 33:555–563. 2000. View Article : Google Scholar : PubMed/NCBI
45	Hynes RO: The extracellular matrix; not just pretty fibrils. Science. 326:1216–1219. 2010. View Article : Google Scholar
46	Yerian L: Identifying activated hepatic stellate cells in chronic and posttransplant recurrent hepatitis C. Liver Transpl. 14:756–758. 2008. View Article : Google Scholar : PubMed/NCBI
47	Friedman SL: The virtuosity of hepatic stellate cells. Gastroenterology. 117:1244–1246. 1999. View Article : Google Scholar : PubMed/NCBI
48	Inagaki Y and Okazaki I: Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 56:284–292. 2007. View Article : Google Scholar : PubMed/NCBI
49	Meindl-Beinker NM and Dooley S: Transforming growth factor-beta and hepatocyte transdifferentiation in liver fibrogenesis. J Gastroenterol Hepatol. 23 (Suppl 1):S122–S127. 2008. View Article : Google Scholar : PubMed/NCBI
50	Arauz J, Zarco N, Segovia J, Shibayama M, Tsutsumi V and Muriel P: Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β. Eur J Gastroenterol Hepatol. 26:164–273. 2014. View Article : Google Scholar : PubMed/NCBI
51	Gressner AM and Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 10:76–99. 2006. View Article : Google Scholar : PubMed/NCBI
52	Mosesson MW: Fibrinogen and fibrin and structure and functions. J Thromb Haemost. 3:1894–1904. 2005. View Article : Google Scholar : PubMed/NCBI
53	Gressner OA, Weiskirchen R and Gressner AM: Biomarkers of liver fibrosis: Clinical translation of molecular pathogenesis or based on liver dependent malfunction tests. Clin Chim Acta. 381:107–113. 2007. View Article : Google Scholar : PubMed/NCBI
54	Kawelke N, Vasel M, Sens C, Au AV, Dooley S and Nakchbandi IA: Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-β. PLoS One. 6:e281812011. View Article : Google Scholar : PubMed/NCBI
55	Liu XY, Liu RX, Hou F, Cui LJ, Li CY, Chi C, Yi E, Wen Y and Yin CH: Fibronectin expression is critical for liver fibrogenesis in vivo and in vitro. Mol Med Rep. 14:3669–3675. 2016. View Article : Google Scholar : PubMed/NCBI
56	Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A and Persico M: Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018:95476132018. View Article : Google Scholar : PubMed/NCBI
57	Meng XM, Chung AC and Lan HY: Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond). 124:243–254. 2013. View Article : Google Scholar : PubMed/NCBI
58	Gandhi GR and Sasikumar P: Antidiabetic effect of Merremia emarginata Burm. F. in streptozotocin induced diabetic rats. Asian Pac J Trop Biomed. 2:281–286. 2012. View Article : Google Scholar : PubMed/NCBI
59	Patanè G, Piro S, Anello M, Rabuazzo AM, Vigneri R and Purrello F: Exposure to glibenclamide increases rat beta cells sensitivity to glucose. Br J Pharmacol. 129:887–892. 2000. View Article : Google Scholar : PubMed/NCBI
60	Oh CS, Kohanim S, Kong FL, Song HC, Huynh N, Mendez R, Chanda M, Edmund Kim E and Yang DJ: Sulfonylurea receptor as a target for molecular imaging of pancreas beta cells with (99m)Tc-DTPA-glipizide. Ann Nucl Med. 26:253–261. 2012. View Article : Google Scholar : PubMed/NCBI
61	Petit P and Loubatières-Mariani MM: Potassium channels of the insulin-secreting B cell. Fundam Clin Pharmacol. 6:123–134. 1992. View Article : Google Scholar : PubMed/NCBI
62	Serrano-Martín X, Payares G and Mendoza-León A: Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob Agents Chemother. 50:4214–4216. 2006. View Article : Google Scholar : PubMed/NCBI
63	Abd EI-Ghffar EA: Ameliorative effect of glabridin, a main component of Glycyrrhiza glaba L. roots in streptozotocin induced Type I diabetes in male albino rats. Indian J Tradit Knowle. 15:570–579. 2016.